Abstract:
Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients.
Methods A total of 85 gynecological malignancy patients in our hospital from July 2013 to June 2017 were divided into the aprepitant group and the control group, according to patients' anti-nausea drug usage.Both groups received chemotherapy and conventional symptomatic treatment; the aprepitant group was added with aprepitant.We observed nausea and vomiting, hemoglobin level and peripheral blood in two groups.
Results The incidence of nausea and vomiting after chemotherapy was lower in the aprepitant group(P < 0.05), but there was no significant difference in the incidence of dizziness, headache or other adverse reactions between two groups (P > 0.05).The decrease of erythrocyte number after chemotherapy in the aprepitant group was slightly less than that in the control group(P > 0.05).
Conclusion The aprepitant could not only effectively prevent the occurrence of chemotherapy-induced nausea and vomiting, improve patients' quality of life and treatment compliance, but also make patients eat early, which is conducive tothe formation of hemoglobin and reducing tumor burden and chemotherapy-induced anemia.
下载:
